Wilford Hall Department of Allergy/Immunology, Wilford Hall Ambulatory Surgical Center, San Antonio, TX, USA.
Allergy Asthma Proc. 2013 Jan-Feb;34(1):19-25. doi: 10.2500/aap.2013.34.3628.
Eosinophilic lung diseases typically present as a triad of pulmonary symptoms, an abnormal chest radiograph, and elevated levels of eosinophils in the sputum and lung tissue. This article focuses on primary causes of eosinophilic lung disease including acute eosinophilic pneumonia, chronic eosinophilic pneumonia, Churg-Strauss syndrome, and hypereosinophilic syndromes. In these disorders elevated eosinophil levels in the tissue lead to inflammation and tissue damage. Peripheral eosinophilia can often be measured when tissue levels are elevated but this is not as reliable a marker as tissue biopsy. Because corticosteroids act through a variety of mechanisms to inhibit eosinophil function and induce apoptosis, they are first-line therapy for eosinophilic lung diseases. Targeted immunosuppressive therapies, such as monoclonal antibodies against key regulatory cytokines for eosinophil production and survival, are not formally approved for eosinophilic lung disease but have shown promising results in published research studies.
嗜酸性粒细胞性肺病通常表现为肺部症状三联征、胸部 X 线异常和痰及肺组织中嗜酸性粒细胞水平升高。本文主要关注嗜酸性粒细胞性肺病的主要病因，包括急性嗜酸性粒细胞性肺炎、慢性嗜酸性粒细胞性肺炎、Churg-Strauss 综合征和高嗜酸性粒细胞综合征。在这些疾病中，组织中嗜酸性粒细胞水平升高会导致炎症和组织损伤。当组织水平升高时，通常可以测量外周血嗜酸性粒细胞增多，但这不如组织活检可靠。由于皮质类固醇通过多种机制抑制嗜酸性粒细胞的功能并诱导其凋亡，因此它们是嗜酸性粒细胞性肺病的一线治疗药物。针对免疫抑制治疗，如针对嗜酸性粒细胞产生和存活的关键调节细胞因子的单克隆抗体，尚未正式批准用于嗜酸性粒细胞性肺病，但在已发表的研究中显示出有前景的结果。
